tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tonix Pharma Secures Defense Contract for Antiviral Development

Tonix Pharma Secures Defense Contract for Antiviral Development

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Tonix Pharma ( (TNXP) ) is now available.

Tonix Pharmaceuticals Holding Corp. has received its first payment from the Defense Threat Reduction Agency to develop antiviral agents aimed at enhancing military personnel’s readiness against biological threats. This strategic focus on broad-spectrum antivirals highlights the company’s potential growth opportunities and underscores the importance of innovation in the defense sector. Investors should note the inherent risks and uncertainties associated with forward-looking statements regarding the company’s future performance.

For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1